[Pertuzumab and solid tumors: perspectives].

Date publication

décembre 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Barthelemy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25532690

Résumé

Over the past decade, trastuzumab was the only available monoclonal anti-HER2 antibody for the treatment of HER2 positive breast and gastric cancer. Recently, pertuzumab added to docetaxel and trastuzumab showed dramatic overall survival improvement in first line treatment of HER2 positive metastatic breast cancer. Pertuzumab is the first approved monoclonal antibody in a new class of drugs called dimerization inhibitors. This agent was also approved in association with trastuzumab for neoadjuvant HER2-positive breast cancer treatment. However, pertuzumab development was not confined to breast cancer and in the present review, we will focus on biological rational, preclinical data and clinical trial results of pertuzumab in solid tumors excluding breast cancer.

Référence

Bull Cancer. 2014 Dec;101(12):1114-21